The Liver Meeting 2014

Summary of presentations from the 65th Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), held in Boston, Massachusetts, USA,  on 7th-11th November 2014

Nezam Hassan Afdhal,1 Graham Foster,2 *Jean-Michel Pawlotsky3,4

1. Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center,  Harvard Medical School, Boston, Massachusetts, USA
2. Queen Mary University of London, Institute of Cell and Molecular Science, London, UK
3. National Reference Center for Viral Hepatitis B, C and D, Department of Virology,  Hôpital Henri Mondor, Université Paris-Est, Créteil, France
4. INSERM U955, Créteil, France
*Correspondence to jean-michel.pawlotsky@hmn.aphp.fr

Acknowledgements: Medical writing assistance was provided by Dr Caroline Charles (Scilink Medical Writing, Biarritz, France).
Support: Gilead financial support via an unrestricted educational grant.
Citation: EMJ Hepatol. 2015;3(Suppl 3):2–19.

Abstract

Rapid developments in clinical research on the hepatitis C virus infection in the last few years have led  to the development of direct-acting antivirals, such as sofosbuvir, simeprevir (both of which have been  approved in the US and Europe since 2014), and daclatasvir, which was approved in Europe only in 2014. These new drugs generated a change of paradigm from interferon-based therapies, as the former  require shorter treatment durations and provide high cure rates with acceptable toxicity. The 65th  American Association for the Study of Liver Diseases (AASLD) Annual Meeting, The Liver Meeting®  2014, took place in Boston, Massachusetts, on 7th-11th November. This review will summarise the highlights  of this meeting within the context of pivotal clinical trials and real-life data on this rapidly evolving  treatment environment, which will assist clinicians in selecting the most appropriate regimen for patients.

Keywords: Hepatitis C virus infection, direct-acting antivirals, sofosbuvir, daclatasvir, ledipasvir, GS-5816, simeprevir.

Disclosure: Nezam H. Afdhal has received research support (within last 2 years) for HCV studies from Merck, Vertex, Gilead, AbbVie and BMS; is a consultant and/or advisory board member for Merck, Gilead, Echosens, Glaxo Smith Kline, Ligand, Springbank, Kadmon, Jannsen, AbbVie, Achillion, and Sandhill Scientific; holds stock or stock options with Springbank; and is the Editor of the Journal of Viral Hepatitis. Graham Foster has received funding from AbbVie, BMS, Boehringer Ingelheim, Gilead, Roche, Merck, Novartis, Springbank, Achillion, Tekmira, and Alnylam. Jean-Michel Pawlotsky has received research grants from Gilead Sciences. He has served as an advisor for  AbbVie, Achillion, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis, and Roche.

Download (PDF, 307KB)

Comments are closed.